Stocks to buy

With shares of ContextLogic (NASDAQ:WISH) up 16% in the past five trading sessions, should investors take a leap of faith on the e-commerce start-up? Source: sdx15 / Shutterstock.com San Francisco-based ContextLogic operates Wish, an e-commerce platform that facilitates transactions between online sellers and buyers. Think of it as a newer, smaller version of eBay (NASDAQ:EBAY).
0 Comments
Compass Pathways (NASDAQ:CMPS) has been beaten up lately. But the fundamentals are rapidly improving, making now a great time to buy this psychedelic stock. Source: Shutterstock CMPS and other companies championing psychedelic-based therapies are seeing legalization tailwinds grow rapidly. Many cities across the U.S. are in talks to decriminalize psilocybin, among other substances. Cities in
0 Comments
History has repeatedly shown that market crashes are almost a “natural” part of the investing cycle. On July 19, the S&P 500 saw its worst single-session plunge in months, fueling speculation that a major correction might be around the corner — and that will provide stocks to buy. The spread of the delta variant, which
0 Comments
Penn National (NASDAQ:PENN) has generated profits in each of the last two quarters — and the company’s first-quarter results were particularly impressive. But that’s not the only reason to like PENN stock. Source: Casimiro PT / Shutterstock.com On top of its quarterly performance, Penn National also looks critically well-positioned to benefit from a meaningful expansion
0 Comments
ContextLogic (NASDAQ:WISH) is well-positioned to benefit from the turbulence that China-based e-commerce companies are facing. Further, after outlining multiple, positive catalysts in my previous column on WISH stock, published on June 28, I have identified several more drivers that are likely to boost the shares over the longer term. Source: sdx15 / Shutterstock.com Among these
0 Comments
Biotechnology company Cassava Sciences (NASDAQ:SAVA) has only two primary product candidates, but they’re highly significant. SAVA stock holders, like all biotech-sector investors, should stay informed on all clinical developments as they’re likely to influence the share price. Source: Shutterstock Cassava Sciences shares are particularly sensitive to news-related events. That’s not a bad thing, though, as the
0 Comments